A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Solid Tumors and Hematologic Malignancy Clinical Trial

Official title:
An Open-Label, Multicenter, Nonrandomized, Dose-Escalation and Tumor-Expansion Phase 1 Study to Evaluate the Safety and Tolerability of INCSHR01210 (Formerly SHR-1210) in Subjects With Advanced Solid Tumors

Status Completed

Clinical Trial Summary

This is an open-label, multicenter, non-randomized, dose escalation and tumor-expansion phase I trial to evaluate safety and tolerability of INCSHR01210 in patients with advanced solid tumors. The trial will enroll subjects with advanced solid tumor who have failed current standard anti-tumor therapies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Neoplasms
Solid Tumors and Hematologic Malignancy

Clinical Trial Details

NCT number	NCT02492789
Study type	Interventional
Source	Atridia Pty Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	September 1, 2015
Completion date	July 5, 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02712905` - An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies	Phase 1/Phase 2
Completed	`NCT01195311` - A Dose-escalation Study in Subjects With Advanced Malignancies	Phase 1
Completed	`NCT00820560` - Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors	Phase 1
Withdrawn	`NCT02355431` - Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations	Phase 2
Terminated	`NCT02431260` - An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies	Phase 1/Phase 2